[{"title":"eFlow Partnering","href":"\/eflow-technology-partnering\/eflow-partnering\/","id":13249,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Customization","href":"\/eflow-technology-partnering\/customization\/","id":5743,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Manufacturing & Supply","href":"\/eflow-technology-partnering\/manufacturing-and-supply\/","id":5781,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Usability & Adherence","href":"\/eflow-technology-partnering\/usability-and-adherence\/","id":5745,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"eHealth & Digital Solutions","href":"\/eflow-technology-partnering\/ehealth-and-digital-solutions\/","id":13237,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Expert Interviews","href":"\/eflow-technology-partnering\/expert-interviews\/","id":11363,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Track Record & Pipeline","href":"\/eflow-technology-partnering\/track-record-and-pipeline\/","id":8767,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"News & Publications","href":"\/eflow-technology-partnering\/news-publications\/","id":15559,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Partner with us","href":"\/eflow-technology-partnering\/partner-with-us\/","id":5757,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"PARI US Patents","href":"\/eflow-technology-partnering\/pari-us-patents\/","id":5869,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"New drug nebulizer combination products","href":"\/eflow-technology-partnering\/new-drug-nebulizer-combination-products\/","id":10545,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"404","href":"\/eflow-technology-partnering\/404\/","id":13217,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"403","href":"\/eflow-technology-partnering\/403\/","id":14617,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Search","href":"\/eflow-technology-partnering\/search\/","id":13215,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Imprint","href":"\/eflow-technology-partnering\/imprint\/","id":10477,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"General Terms and conditions","href":"\/eflow-technology-partnering\/general-terms-and-conditions\/","id":14639,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Data Protection","href":"\/eflow-technology-partnering\/data-protection\/","id":10479,"breadcrumb":" \u00b7 eFlow Partnering"},{"title":"Categories","href":"\/eflow-technology-partnering\/news-publications\/categories\/","id":15561,"breadcrumb":"News & Publications"},{"title":"Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis","href":"\/eflow-technology-partnering\/news-publications\/avalyn-completes-target-enrollment-in-phase-2b-mist-trial-of-ap01-inhaled-pirfenidone-for-patients-with-progressive-pulmonary-fibrosis\/","id":15584,"breadcrumb":"News & Publications"},{"title":"Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001","href":"\/eflow-technology-partnering\/news-publications\/enterprise-therapeutics-achieves-primary-efficacy-outcome-in-phase-2-clinical-trial-for-cystic-fibrosis-with-novel-inhaled-enac-blocker-etd001\/","id":15837,"breadcrumb":"News & Publications"},{"title":"Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap\/","id":15563,"breadcrumb":"News & Publications"},{"title":"Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap-1\/","id":15586,"breadcrumb":"News & Publications"},{"title":"Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE\u00ae (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease","href":"\/eflow-technology-partnering\/news-publications\/insmed-announces-positive-topline-results-from-phase-3b-encore-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease\/","id":15588,"breadcrumb":"News & Publications"},{"title":"Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis","href":"\/eflow-technology-partnering\/news-publications\/avalyn-announces-first-patient-dosed-in-aura-phase-2-clinical-trial-evaluating-ap02-inhaled-nintedanib-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","id":15590,"breadcrumb":"News & Publications"},{"title":"Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow\u00ae Nebulizer System","href":"\/eflow-technology-partnering\/news-publications\/savara-and-pari-granted-a-european-patent-covering-the-drug-device-combination-of-molbreevi-delivered-via-the-proprietary-eflowr-nebulizer-system\/","id":15592,"breadcrumb":"News & Publications"},{"title":"Customization is key","href":"\/eflow-technology-partnering\/news-publications\/customization-is-key\/","id":15594,"breadcrumb":"News & Publications"},{"title":"Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-completes-submission-of-the-biologics-license-application-bla-to-the-us-food-and-drug-administration-fda-for-molbreevi-as-a-treatment-for-autoimmune-pulmonary-alveolar-proteinosis-apap\/","id":15596,"breadcrumb":"News & Publications"},{"title":"Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-manuscript-on-long-term-outcomes-with-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-published-in-erj-open-research\/","id":15598,"breadcrumb":"News & Publications"},{"title":"Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-initiates-rolling-submission-of-a-biologics-license-application-bla-to-the-us-food-and-drug-administration-fda-for-molbreevi-for-the-potential-treatment-of-autoimmune-pulmonary-alveolar-proteinosis-apap\/","id":15625,"breadcrumb":"News & Publications"},{"title":"Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-molgramostim-nebulizer-solution-molgramostim-achieved-statistical-significance-for-primary-endpoint-and-multiple-secondary-endpoints-in-impala-2-a-pivotal-phase-3-clinical-trial-in-autoimmune-pulmonary-alveolar-proteinosis-apap\/","id":15627,"breadcrumb":"News & Publications"},{"title":"Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis","href":"\/eflow-technology-partnering\/news-publications\/renovion-announces-positive-top-line-results-from-phase-2-climb-study-of-arina-1-rvn-301-in-patients-with-non-cystic-fibrosis-bronchiectasis\/","id":15629,"breadcrumb":"News & Publications"},{"title":"Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE\u00ae (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC","href":"\/eflow-technology-partnering\/news-publications\/insmed-announces-positive-topline-results-from-phase-3-arise-study-of-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-ntm-lung-disease-caused-by-mac\/","id":15631,"breadcrumb":"News & Publications"},{"title":"Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-completes-enrollment-of-pivotal-phase-3-impala-2-trial-of-molgramostim-nebulizer-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap\/","id":15633,"breadcrumb":"News & Publications"},{"title":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)","href":"\/eflow-technology-partnering\/news-publications\/zambon-completes-enrollment-in-phase-3-clinical-development-program-evaluating-liposomal-cyclosporine-a-for-inhalation-l-csa-i-in-patients-with-bronchiolitis-obliterans-syndrome-bos\/","id":15635,"breadcrumb":"News & Publications"},{"title":"First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant","href":"\/eflow-technology-partnering\/news-publications\/first-patient-enrolled-in-phase-3-clinical-trial-evaluating-arina-1-in-lung-transplant\/","id":15637,"breadcrumb":"News & Publications"},{"title":"Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis","href":"\/eflow-technology-partnering\/news-publications\/avalyn-pharma-reports-results-of-phase-1-study-of-ap02-in-healthy-volunteers-and-participants-with-idiopathic-pulmonary-fibrosis\/","id":15639,"breadcrumb":"News & Publications"},{"title":"Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients","href":"\/eflow-technology-partnering\/news-publications\/renovion-receives-fda-fast-track-designation-for-arina-1-for-the-prevention-of-bos-progression-in-lung-transplant-patients\/","id":15641,"breadcrumb":"News & Publications"},{"title":"Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile","href":"\/eflow-technology-partnering\/news-publications\/avalyn-pharma-publishes-phase-1b-atlas-results-demonstrating-stabilization-of-lung-function-at-24-and-48-weeks-with-ap01-and-favorable-safety-profile\/","id":15643,"breadcrumb":"News & Publications"},{"title":"ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia","href":"\/eflow-technology-partnering\/news-publications\/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-trial-of-novel-disease-modifying-genetic-medicine-rct1100-for-the-treatment-of-primary-ciliary-dyskinesia\/","id":15645,"breadcrumb":"News & Publications"},{"title":"Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound","href":"\/eflow-technology-partnering\/news-publications\/spexis-reports-solid-safety-and-pharmacokinetics-results-from-first-in-human-study-with-inhaled-murepavadin-a-novel-macrocycle-compound\/","id":15647,"breadcrumb":"News & Publications"},{"title":"First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE","href":"\/eflow-technology-partnering\/news-publications\/first-patient-enrolled-in-phase-2-clinical-study-evaluating-arina-1-for-the-treatment-of-ncfbe\/","id":15649,"breadcrumb":"News & Publications"},{"title":"Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","href":"\/eflow-technology-partnering\/news-publications\/savara-awarded-promising-innovative-medicine-pim-designation-in-the-united-kingdom-uk-for-molgramostim-nebulizer-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap\/","id":15651,"breadcrumb":"News & Publications"},{"title":"Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program","href":"\/eflow-technology-partnering\/news-publications\/renovion-receives-notice-of-study-may-proceed-status-for-lung-transplant-program\/","id":15653,"breadcrumb":"News & Publications"},{"title":"Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic","href":"\/eflow-technology-partnering\/news-publications\/savara-awarded-innovation-passport-in-united-kingdom-uk-for-molgramostim-nebulizer-solution-molgramostim-a-novel-investigational-inhaled-biologic\/","id":15655,"breadcrumb":"News & Publications"},{"title":"Polyphor closes merger with EnBiotix and is renamed Spexis","href":"\/eflow-technology-partnering\/news-publications\/polyphor-closes-merger-with-enbiotix-and-is-renamed-spexis\/","id":15657,"breadcrumb":"News & Publications"},{"title":"Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-first-patient-dosed-in-pivotal-phase-3-autoimmune-pulmonary-alveolar-proteinosis-apap-trial\/","id":15659,"breadcrumb":"News & Publications"},{"title":"Dr. Stefan Seemann is appointed President of PARI Pharma GmbH","href":"\/eflow-technology-partnering\/news-publications\/dr-stefan-seemann-is-appointed-president-of-pari-pharma-gmbh\/","id":15661,"breadcrumb":"News & Publications"},{"title":"Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial\u200b","href":"\/eflow-technology-partnering\/news-publications\/avalyn-pharma-reports-statistically-significant-dose-response-with-aerosolized-pirfenidone-in-an-idiopathic-pulmonary-fibrosis-trial\/","id":15663,"breadcrumb":"News & Publications"},{"title":"Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference\u200b\u200b\u200b\u200b","href":"\/eflow-technology-partnering\/news-publications\/insmed-presents-broad-range-of-data-across-its-three-programs-at-the-american-thoracic-society-2021-international-conference\/","id":15665,"breadcrumb":"News & Publications"},{"title":"Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021","href":"\/eflow-technology-partnering\/news-publications\/key-data-on-economic-impact-of-bronchiolitis-obliterans-syndrome-bos-presented-at-ishlt-2021\/","id":15667,"breadcrumb":"News & Publications"},{"title":"LAMIRA\u00ae, an eFlow\u00ae Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE\u00ae (amikacin liposome inhalation suspension)","href":"\/eflow-technology-partnering\/news-publications\/lamirar-an-eflowr-technology-nebulizer-expected-to-launch-in-japan-as-a-medical-device-for-exclusive-administration-of-arikaycer-amikacin-liposome-inhalation-suspension\/","id":15669,"breadcrumb":"News & Publications"},{"title":"Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial","href":"\/eflow-technology-partnering\/news-publications\/santhera-announces-positive-results-with-lonodelestat-in-early-phase-cystic-fibrosis-trial\/","id":15671,"breadcrumb":"News & Publications"},{"title":"Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE\u00ae (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease","href":"\/eflow-technology-partnering\/news-publications\/insmed-initiates-frontline-clinical-trial-program-for-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-mac-lung-disease\/","id":15673,"breadcrumb":"News & Publications"},{"title":"Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin","href":"\/eflow-technology-partnering\/news-publications\/polyphor-receives-approval-to-start-first-in-human-clinical-trial-of-inhaled-antibiotic-murepavadin\/","id":15675,"breadcrumb":"News & Publications"},{"title":"Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin","href":"\/eflow-technology-partnering\/news-publications\/polyphor-receives-award-of-up-to-usd-33-million-from-cystic-fibrosis-foundation-to-support-clinical-development-of-inhaled-murepavadin\/","id":15677,"breadcrumb":"News & Publications"},{"title":"LAMIRA\u00ae, an eFlow\u00ae Technology nebulizer, is the only device to deliver Insmed\u2019s ARIKAYCE\u00ae Liposomal 590 mg Nebuliser Dispersion in the European Union","href":"\/eflow-technology-partnering\/news-publications\/lamirar-an-eflowr-technology-nebulizer-is-the-only-device-to-deliver-insmeds-arikaycer-liposomal-590-mg-nebuliser-dispersion-in-the-european-union\/","id":15679,"breadcrumb":"News & Publications"},{"title":"PARI's optimized Investigational eFlow\u00ae Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis\u00b4 Phase 1\/2a clinical trial","href":"\/eflow-technology-partnering\/news-publications\/paris-optimized-investigational-eflowr-technology-nebulizer-delivering-well-tolerated-aerosols-of-ar-501-in-aridis-phase-12a-clinical-trial\/","id":15681,"breadcrumb":"News & Publications"},{"title":"Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial","href":"\/eflow-technology-partnering\/news-publications\/avalyn-pharma-reports-update-in-ongoing-idiopathic-pulmonary-fibrosis-trial\/","id":15683,"breadcrumb":"News & Publications"},{"title":"Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis","href":"\/eflow-technology-partnering\/news-publications\/ionis-inhaled-antisense-medicine-demonstrates-potential-as-a-novel-treatment-for-cystic-fibrosis\/","id":15685,"breadcrumb":"News & Publications"},{"title":"Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options","href":"\/eflow-technology-partnering\/news-publications\/insmed-receives-positive-chmp-opinion-for-arikayce-liposomal-590-mg-nebuliser-dispersion-for-the-treatment-of-ntm-lung-infections-caused-by-mac-in-non-cf-patients-with-limited-treatment-options\/","id":15687,"breadcrumb":"News & Publications"},{"title":"New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE\u00ae (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease","href":"\/eflow-technology-partnering\/news-publications\/new-ntm-treatment-guidelines-recommend-insmeds-arikaycer-amikacin-liposome-inhalation-suspension-for-treatment-of-patients-with-refractory-mac-lung-disease\/","id":15689,"breadcrumb":"News & Publications"},{"title":"Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases","href":"\/eflow-technology-partnering\/news-publications\/renovion-announces-completion-of-81-million-financing-round-enabling-clinical-programs-in-chronic-inflammatory-lung-diseases\/","id":15691,"breadcrumb":"News & Publications"},{"title":"Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference","href":"\/eflow-technology-partnering\/news-publications\/biomarck-pharmaceuticals-to-present-expanded-analysis-of-bio-11006-clinical-data-in-treatment-of-non-small-cell-lung-cancer-at-the-american-thoracic-society-2020-international-conference\/","id":15695,"breadcrumb":"News & Publications"},{"title":"A new FDA Fast Track designation for Zambon","href":"\/eflow-technology-partnering\/news-publications\/a-new-fda-fast-track-designation-for-zambon\/","id":15697,"breadcrumb":"News & Publications"},{"title":"Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)","href":"\/eflow-technology-partnering\/news-publications\/breath-therapeutics-a-zambon-company-initiates-boston-3-and-boston-4-two-additional-clinical-studies-for-the-treatment-of-bronchiolitis-obliterans-syndrome-bos\/","id":15699,"breadcrumb":"News & Publications"},{"title":"Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency","href":"\/eflow-technology-partnering\/news-publications\/kamada-announces-enrollment-of-first-patient-into-its-pivotal-phase-3-innovaate-clinical-trial-of-inhaled-aat-for-the-treatment-of-alpha-1-antitrypsin-deficiency\/","id":15701,"breadcrumb":"News & Publications"},{"title":"Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis","href":"\/eflow-technology-partnering\/news-publications\/santhera-announces-publication-of-phase-i-clinical-data-with-pol6014-in-journal-of-cystic-fibrosis\/","id":15703,"breadcrumb":"News & Publications"},{"title":"PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma","href":"\/eflow-technology-partnering\/news-publications\/pari-pharma-spin-out-breath-therapeutics-acquired-by-zambon-pharma\/","id":15705,"breadcrumb":"News & Publications"},{"title":"New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE\u00ae (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease","href":"\/eflow-technology-partnering\/news-publications\/new-phase-3-data-show-sustainability-and-durability-of-culture-conversion-with-arikaycer-amikacin-liposome-inhalation-suspension-in-patients-with-refractory-mac-lung-disease\/","id":15707,"breadcrumb":"News & Publications"},{"title":"Sunovion to Present Data on LONHALA\u00ae MAGNAIR\u00ae Inhalation Solution and COPD at the American Thoracic Society International Conference 2019","href":"\/eflow-technology-partnering\/news-publications\/sunovion-to-present-data-on-lonhalar-magnairr-inhalation-solution-and-copd-at-the-american-thoracic-society-international-conference-2019\/","id":15709,"breadcrumb":"News & Publications"},{"title":"Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.","href":"\/eflow-technology-partnering\/news-publications\/breath-therapeutics-announces-initiation-of-global-phase-3-trials-for-the-treatment-of-bronchiolitis-obliterans-syndrome\/","id":15711,"breadcrumb":"News & Publications"},{"title":"PARI Pharma\u2019s eFlow\u00ae Technology device, LAMIRA\u2122, approved as the only nebulizer system to deliver Insmed\u2019s ARIKAYCE\u00ae (amikacin liposome inhalation suspension).","href":"\/eflow-technology-partnering\/news-publications\/pari-pharmas-eflowr-technology-device-lamiratm-approved-as-the-only-nebulizer-system-to-deliver-insmeds-arikaycer-amikacin-liposome-inhalation-suspension\/","id":15713,"breadcrumb":"News & Publications"},{"title":"MagnairTM an eFlow\u00ae Closed System Nebulizer together with Sunovion\u2019s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)","href":"\/eflow-technology-partnering\/news-publications\/magnairtm-an-eflowr-closed-system-nebulizer-together-with-sunovions-lonhalatm-is-the-first-eflow-technology-based-product-to-receive-fda-approval-to-treat-chronic-obstructive-pulmonary-disease-copd\/","id":15715,"breadcrumb":"News & Publications"},{"title":"A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser","href":"\/eflow-technology-partnering\/news-publications\/savara-announces-manuscript-on-long-term-outcomes-with-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-published-in-erj-open-research-1-2\/","id":15610,"breadcrumb":"News & Publications"},{"title":"From Continuity to Competitive Edge \u2013 How Long-Term Collaboration Drives HF Program Success","href":"\/eflow-technology-partnering\/news-publications\/from-continuity-to-competitive-edge-how-long-term-collaboration-drives-hf-program-success\/","id":15602,"breadcrumb":"News & Publications"},{"title":"A Novel HF User Characteristics Assessment Approach for a New Platform-Based, Breath-Triggered Nebulizer in Inhalation Therapy","href":"\/eflow-technology-partnering\/news-publications\/a-novel-hf-user-characteristics-assessment-approach-for-a-new-platform-based-breath-triggered-nebulizer-in-inhalation-therapy\/","id":15600,"breadcrumb":"News & Publications"},{"title":"The Importance of Mesh Nebulizer Configuration in mRNA-LNP Delivery Performance","href":"\/eflow-technology-partnering\/news-publications\/the-importance-of-mesh-nebulizer-configuration-in-mrna-lnp-delivery-performance\/","id":15604,"breadcrumb":"News & Publications"},{"title":"Effect of Nebulizer Breath-Guiding on Breathing Patterns","href":"\/eflow-technology-partnering\/news-publications\/effect-of-nebulizer-breath-guiding-on-breathing-patterns\/","id":15606,"breadcrumb":"News & Publications"},{"title":"Analysis of mRNA Delivery Performance via Vibrating Mesh Nebulization","href":"\/eflow-technology-partnering\/news-publications\/analysis-of-mrna-delivery-performance-via-vibrating-mesh-nebulization\/","id":15612,"breadcrumb":"News & Publications"},{"title":"Preclinical concept studies showing advantage of an inhaled anti-CTGF\/CCN2 protein for pulmonary fibrosis treatment","href":"\/eflow-technology-partnering\/news-publications\/a-novel-hf-user-characteristics-assessment-approach-for-a-new-platform-based-breath-triggered-nebulizer-in-inhalation-therapy-1\/","id":15614,"breadcrumb":"News & Publications"},{"title":"Long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution","href":"\/eflow-technology-partnering\/news-publications\/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution\/","id":15616,"breadcrumb":"News & Publications"},{"title":"eFlow Integrated \u2013 Aerosol Performance of a Novel Breath-Triggered Nebulizer","href":"\/eflow-technology-partnering\/news-publications\/eflow-integrated-aerosol-performance-of-a-novel-breath-triggered-nebulizer\/","id":15719,"breadcrumb":"News & Publications"},{"title":"Optimising inhalation adherence and technique: The power of digital technology","href":"\/eflow-technology-partnering\/news-publications\/optimising-inhalation-adherence-and-technique-the-power-of-digital-technology\/","id":15721,"breadcrumb":"News & Publications"},{"title":"Deep breaths, deep dives: The new eFlow Integrated nebuliser","href":"\/eflow-technology-partnering\/news-publications\/deep-breaths-deep-dives-the-new-eflow-integrated-nebuliser\/","id":15723,"breadcrumb":"News & Publications"},{"title":"Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.","href":"\/eflow-technology-partnering\/news-publications\/safety-and-efficacy-of-the-epithelial-sodium-channel-blocker-idrevloride-in-people-with-primary-ciliary-dyskinesia-clean-pcd-a-multinational-phase-2-randomised-double-blind-placebo-controlled-crossover-trial\/","id":15725,"breadcrumb":"News & Publications"},{"title":"Large-eddy simulation, convective instability, and modal causality of coaxial supersonic air\u2013water jets considering a swirl effect.","href":"\/eflow-technology-partnering\/news-publications\/large-eddy-simulation-convective-instability-and-modal-causality-of-coaxial-supersonic-air-water-jets-considering-a-swirl-effect\/","id":15727,"breadcrumb":"News & Publications"},{"title":"Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.","href":"\/eflow-technology-partnering\/news-publications\/mucosal-adenoviral-vectored-vaccine-boosting-durably-prevents-xbb116-infection-in-nonhuman-primates\/","id":15729,"breadcrumb":"News & Publications"},{"title":"Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.","href":"\/eflow-technology-partnering\/news-publications\/aerosol-delivery-of-sars-cov-2-human-monoclonal-antibodies-in-macaques-limits-viral-replication-and-lung-pathology\/","id":15731,"breadcrumb":"News & Publications"},{"title":"Transient Aerosol Measurements: Assessing the eFlow Nebulizer Aerosol Bolus.","href":"\/eflow-technology-partnering\/news-publications\/transient-aerosol-measurements-assessing-the-eflow-nebulizer-aerosol-bolus\/","id":15733,"breadcrumb":"News & Publications"},{"title":"Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.","href":"\/eflow-technology-partnering\/news-publications\/nebulization-of-pegylated-recombinant-human-deoxyribonuclease-i-using-vibrating-membrane-nebulizers-a-technical-feasibility-study\/","id":15735,"breadcrumb":"News & Publications"},{"title":"Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose\u2013response trial.","href":"\/eflow-technology-partnering\/news-publications\/inhaled-pirfenidone-solution-ap01-for-ipf-a-randomised-open-label-dose-response-trial\/","id":15737,"breadcrumb":"News & Publications"},{"title":"Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis.","href":"\/eflow-technology-partnering\/news-publications\/differential-performance-and-lung-deposition-of-levofloxacin-with-different-nebulisers-used-in-cystic-fibrosis\/","id":15739,"breadcrumb":"News & Publications"},{"title":"A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation.","href":"\/eflow-technology-partnering\/news-publications\/a-randomized-controlled-trial-of-liposomal-cyclosporine-a-for-inhalation-in-the-prevention-of-bronchiolitis-obliterans-syndrome-following-lung-transplantation\/","id":15741,"breadcrumb":"News & Publications"},{"title":"Inhaled Medicines: Past, Present, and Future","href":"\/eflow-technology-partnering\/news-publications\/inhaled-medicines-past-present-and-future\/","id":15743,"breadcrumb":"News & Publications"},{"title":"Unsteady Aerosol Output Rate Measurements: Assessing the eFlow Nebulizer Aerosol Bolus.","href":"\/eflow-technology-partnering\/news-publications\/unsteady-aerosol-output-rate-measurements-assessing-the-eflow-nebulizer-aerosol-bolus\/","id":15745,"breadcrumb":"News & Publications"},{"title":"Towards More Realistic In Vitro Nebulizer Testing.","href":"\/eflow-technology-partnering\/news-publications\/towards-more-realistic-in-vitro-nebulizer-testing\/","id":15747,"breadcrumb":"News & Publications"},{"title":"Development of a Novel Test Stand for the Measurement of Valved Holding Chambers with Facemasks.","href":"\/eflow-technology-partnering\/news-publications\/development-of-a-novel-test-stand-for-the-measurement-of-valved-holding-chambers-with-facemasks\/","id":15749,"breadcrumb":"News & Publications"},{"title":"eFlow Technology Nebulisers with Digital Therapy Management: The PARI Connect Eco-System.","href":"\/eflow-technology-partnering\/news-publications\/eflow-technology-nebulisers-with-digital-therapy-management-the-pari-connect-eco-system\/","id":15751,"breadcrumb":"News & Publications"},{"title":"Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.","href":"\/eflow-technology-partnering\/news-publications\/deposition-of-inhaled-levofloxacin-in-cystic-fibrosis-lungs-assessed-by-functional-respiratory-imaging\/","id":15753,"breadcrumb":"News & Publications"},{"title":"Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.","href":"\/eflow-technology-partnering\/news-publications\/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-18\/","id":15755,"breadcrumb":"News & Publications"},{"title":"Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.","href":"\/eflow-technology-partnering\/news-publications\/self-management-intervention-to-reduce-pulmonary-exacerbations-by-supporting-treatment-adherence-in-adults-with-cystic-fibrosis-a-randomised-controlled-trial\/","id":15757,"breadcrumb":"News & Publications"},{"title":"The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in Pseudomonas aeruginosa Isolates in Cystic Fibrosis.","href":"\/eflow-technology-partnering\/news-publications\/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-20\/","id":15759,"breadcrumb":"News & Publications"},{"title":"Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow\u00ae Technology.","href":"\/eflow-technology-partnering\/news-publications\/robustness-of-aerosol-delivery-of-amikacin-liposome-inhalation-suspension-using-the-eflowr-technology\/","id":15761,"breadcrumb":"News & Publications"},{"title":"Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub.","href":"\/eflow-technology-partnering\/news-publications\/development-of-an-intervention-to-increase-adherence-to-nebuliser-treatment-in-adults-with-cystic-fibrosis-cfhealthhub\/","id":15763,"breadcrumb":"News & Publications"},{"title":"How Cold Is Cold Enough? Refrigeration of the Next-Generation Impactor to Prevent Aerosol Undersizing.","href":"\/eflow-technology-partnering\/news-publications\/how-cold-is-cold-enough-refrigeration-of-the-next-generation-impactor-to-prevent-aerosol-undersizing\/","id":15765,"breadcrumb":"News & Publications"},{"title":"Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.","href":"\/eflow-technology-partnering\/news-publications\/improvement-in-lung-function-and-patient-reported-outcomes-in-patients-with-copd-with-comorbid-anxiety-and-depression-receiving-nebulized-glycopyrrolate-in-the-golden-3-and-4-studies\/","id":15767,"breadcrumb":"News & Publications"},{"title":"Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.","href":"\/eflow-technology-partnering\/news-publications\/inhaled-molgramostim-therapy-in-autoimmune-pulmonary-alveolar-proteinosis\/","id":15769,"breadcrumb":"News & Publications"},{"title":"Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow\u00ae nebulizer.","href":"\/eflow-technology-partnering\/news-publications\/improved-bioavailability-of-cromolyn-sodium-using-inhaled-pa101-delivered-via-eflowr-nebulizer\/","id":15771,"breadcrumb":"News & Publications"},{"title":"Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate\/eFlow\u00ae CS.","href":"\/eflow-technology-partnering\/news-publications\/observational-real-world-study-to-assess-clinical-characteristics-and-device-satisfaction-in-patients-with-copd-treated-with-glycopyrrolateeflowr-cs\/","id":15773,"breadcrumb":"News & Publications"},{"title":"Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.","href":"\/eflow-technology-partnering\/news-publications\/aerosol-pirfenidone-pharmacokinetics-after-inhaled-delivery-in-sheep-a-viable-approach-to-treating-idiopathic-pulmonary-fibrosis\/","id":15775,"breadcrumb":"News & Publications"},{"title":"Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.","href":"\/eflow-technology-partnering\/news-publications\/making-concentrated-antibody-formulations-accessible-for-vibrating-mesh-nebulization\/","id":15777,"breadcrumb":"News & Publications"},{"title":"A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.","href":"\/eflow-technology-partnering\/news-publications\/a-randomized-double-blinded-placebo-controlled-dose-escalation-phase-1-study-of-aerosolized-pirfenidone-delivered-via-the-pari-investigational-eflow-nebulizer-in-volunteers-and-patients-with-idiopathic-pulmonary-fibrosis\/","id":15779,"breadcrumb":"News & Publications"},{"title":"A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation.","href":"\/eflow-technology-partnering\/news-publications\/a-randomised-single-centre-trial-of-inhaled-liposomal-cyclosporine-for-bronchiolitis-obliterans-syndrome-post-lung-transplantation\/","id":15781,"breadcrumb":"News & Publications"},{"title":"Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.","href":"\/eflow-technology-partnering\/news-publications\/single-dose-escalation-studies-with-inhaled-pol6014-a-potent-novel-selective-reversible-inhibitor-of-human-neutrophil-elastase-in-healthy-volunteers-and-subjects-with-cystic-fibrosis\/","id":15783,"breadcrumb":"News & Publications"},{"title":"Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.","href":"\/eflow-technology-partnering\/news-publications\/topical-application-of-nebulized-human-igg-iga-and-igam-in-the-lungs-of-rats-and-non-human-primates\/","id":15785,"breadcrumb":"News & Publications"},{"title":"In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution.","href":"\/eflow-technology-partnering\/news-publications\/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-34\/","id":15787,"breadcrumb":"News & Publications"},{"title":"Monitoring nebuliser usage & lung function in clinical trials.","href":"\/eflow-technology-partnering\/news-publications\/monitoring-nebuliser-usage-lung-function-in-clinical-trials\/","id":15789,"breadcrumb":"News & Publications"},{"title":"Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack).","href":"\/eflow-technology-partnering\/news-publications\/monitoring-adherence-to-treatment-regimen-of-inhaled-medication-use-in-a-clinical-trial-with-an-investigational-eflow-nebulizer-etrack\/","id":15791,"breadcrumb":"News & Publications"},{"title":"Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.","href":"\/eflow-technology-partnering\/news-publications\/randomized-trial-of-efficacy-and-safety-of-dornase-alfa-delivered-by-erapid-nebulizer-in-cystic-fibrosis-patients\/","id":15793,"breadcrumb":"News & Publications"},{"title":"In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent\u00ae).","href":"\/eflow-technology-partnering\/news-publications\/in-vitro-study-of-aerosolised-colistin-delivered-to-the-nasal-tract-via-a-pulsating-aerosol-delivery-device-vibrentr\/","id":15795,"breadcrumb":"News & Publications"},{"title":"Drug delivery to paranasal sinuses using pulsating aerosols.","href":"\/eflow-technology-partnering\/news-publications\/drug-delivery-to-paranasal-sinuses-using-pulsating-aerosols\/","id":15797,"breadcrumb":"News & Publications"},{"title":"The eFlow \u2018\u2018closed system\u2019\u2019(CS) - a novel device platform for liquid aerosol drug-device combinations.","href":"\/eflow-technology-partnering\/news-publications\/the-eflow-closed-systemcs-a-novel-device-platform-for-liquid-aerosol-drug-device-combinations\/","id":15799,"breadcrumb":"News & Publications"},{"title":"A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.","href":"\/eflow-technology-partnering\/news-publications\/a-pharmacokinetics-and-safety-comparison-of-a-highly-concentrated-tobramycin-solution-with-tobi\/","id":15801,"breadcrumb":"News & Publications"},{"title":"Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.","href":"\/eflow-technology-partnering\/news-publications\/some-cystic-fibrosis-patients-do-not-tolerate-tobramycin-dry-powder-inhalation\/","id":15803,"breadcrumb":"News & Publications"},{"title":"Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.","href":"\/eflow-technology-partnering\/news-publications\/topical-drug-delivery-in-chronic-rhinosinusitis-patients-before-and-after-sinus-surgery-using-pulsating-aerosols\/","id":15805,"breadcrumb":"News & Publications"},{"title":"Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.","href":"\/eflow-technology-partnering\/news-publications\/long-term-outcomes-in-five-patients-with-autoimmune-pulmonary-alveolar-proteinosis-treated-with-molgramostim-inhalation-solution-1-44\/","id":15807,"breadcrumb":"News & Publications"},{"title":"Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.","href":"\/eflow-technology-partnering\/news-publications\/assessing-modeled-co2-retention-and-rebreathing-of-a-facemask-designed-for-efficient-delivery-of-aerosols-to-infants\/","id":15809,"breadcrumb":"News & Publications"},{"title":"A Comparison of Amount and Speed of Deposition Between the PARI LC STAR\u00ae Jet Nebulizer and an Investigational eFlow\u00ae Nebulizer.","href":"\/eflow-technology-partnering\/news-publications\/a-comparison-of-amount-and-speed-of-deposition-between-the-pari-lc-starr-jet-nebulizer-and-an-investigational-eflowr-nebulizer\/","id":15811,"breadcrumb":"News & Publications"},{"title":"Nasally inhaled pulsating aerosols: lung, sinus and nose deposition.","href":"\/eflow-technology-partnering\/news-publications\/nasally-inhaled-pulsating-aerosols-lung-sinus-and-nose-deposition\/","id":15819,"breadcrumb":"News & Publications"},{"title":"Objective Evaluation of Adherence to Inhaled Liposomal Cyclosporin Therapy for Lung Transplant Patients in a Clinical Trial.","href":"\/eflow-technology-partnering\/news-publications\/objective-evaluation-of-adherence-to-inhaled-liposomal-cyclosporin-therapy-for-lung-transplant-patients-in-a-clinical-trial\/","id":15817,"breadcrumb":"News & Publications"},{"title":"Pulsating aerosols for drug delivery to the sinuses in healthy volunteers.","href":"\/eflow-technology-partnering\/news-publications\/pulsating-aerosols-for-drug-delivery-to-the-sinuses-in-healthy-volunteers\/","id":15813,"breadcrumb":"News & Publications"},{"title":"Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation.","href":"\/eflow-technology-partnering\/news-publications\/lung-deposition-of-a-liposomal-cyclosporine-a-inhalation-solution-in-patients-after-lung-transplantation\/","id":15815,"breadcrumb":"News & Publications"},{"title":"A Novel Nebuliser for the Simultaneous Administration of siRNA and Supplemental Oxygen for RSV in Infants.","href":"\/eflow-technology-partnering\/news-publications\/a-novel-nebuliser-for-the-simultaneous-administration-of-sirna-and-supplemental-oxygen-for-rsv-in-infants\/","id":15821,"breadcrumb":"News & Publications"},{"title":"New advances in aerosolised drug delivery: vibrating membrane nebuliser technology.","href":"\/eflow-technology-partnering\/news-publications\/new-advances-in-aerosolised-drug-delivery-vibrating-membrane-nebuliser-technology\/","id":15823,"breadcrumb":"News & Publications"},{"title":"The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems.","href":"\/eflow-technology-partnering\/news-publications\/the-customised-electronic-nebuliser-a-new-category-of-liquid-aerosol-drug-delivery-systems\/","id":15825,"breadcrumb":"News & Publications"},{"title":"Drug Delivery to the Lungs (DDL) Conference","href":"\/eflow-technology-partnering\/news-and-publications\/drug-delivery-to-the-lungs-ddl-conference\/","id":8577,"breadcrumb":"News & Publications"},{"title":"News-Tuesday-02-October-2018","href":"\/eflow-technology-partnering\/news-and-publications\/news-tuesday-02-october-2018\/","id":5915,"breadcrumb":"News & Publications"},{"title":"News-Thursday-07-Dezember-2017","href":"\/eflow-technology-partnering\/news-and-publications\/news-thursday-07-dezember-2017\/","id":5913,"breadcrumb":"News & Publications"},{"title":"News-Tuesday-02-October-2018-1","href":"\/eflow-technology-partnering\/news-and-publications\/news-tuesday-02-october-2018-1\/","id":10357,"breadcrumb":"News & Publications"},{"title":"News-Wednesday-28-October-2020","href":"\/eflow-technology-partnering\/news-and-publications\/news-wednesday-28-october-2020\/","id":10365,"breadcrumb":"News & Publications"},{"title":"News-Tuesday-23-March-2021","href":"\/eflow-technology-partnering\/news-and-publications\/news-tuesday-23-march-2021\/","id":10707,"breadcrumb":"News & Publications"},{"title":"News-Friday-25-June-2021","href":"\/eflow-technology-partnering\/news-and-publications\/news-friday-25-june-2021\/","id":11255,"breadcrumb":"News & Publications"},{"title":"Thank you!","href":"\/eflow-technology-partnering\/partner-with-us\/thank-you-for-your-e-mail\/","id":5761,"breadcrumb":"Partner with us"},{"title":"Cookie Consent","href":"\/eflow-technology-partnering\/data-protection\/cookie-consent\/","id":13307,"breadcrumb":"Data Protection"},{"title":"General Privacy Policy","href":"\/eflow-technology-partnering\/data-protection\/general-privacy-policy\/","id":10481,"breadcrumb":"Data Protection"},{"title":"Privacy Policy Internet","href":"\/eflow-technology-partnering\/data-protection\/privacy-policy-internet\/","id":10487,"breadcrumb":"Data Protection"},{"title":"Privacy Policy REXX Applicant Portal","href":"\/eflow-technology-partnering\/data-protection\/privacy-policy-rexx-applicant-portal\/","id":10485,"breadcrumb":"Data Protection"},{"title":"Privacy Policy Social Networks","href":"\/eflow-technology-partnering\/privacy-policy-social-networks\/","id":10483,"breadcrumb":"Data Protection"}]